SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

This study has been completed.
Sponsor:
Information provided by:
Abbott Vascular
ClinicalTrials.gov Identifier:
NCT00180310
First received: September 11, 2005
Last updated: July 18, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2011
  Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Publications:
Serruys, P., Ruygrok, P., Neuzner, J., Et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention: 2;286-294, 2006
Ruygrok, P., Desaga, M., Van Den Branden, F., et al. One year clinical follow-up or the XIENCE V Everolimus-eluting stent system in the treatment of de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention:3; 315-320, 2007.
Khattab, Ahmed A., et. al. Differentiated analysis of an evrolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. EuroIntervention 3(5): 566-573, 2008
SPIRIT II study: A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Serruys Patrick W (Reprint). Erasmus MC, Ctr Thorax, Rotterdam, Netherlands. Journal of the American College of Cardiology 51 ( 10, Suppl. A ): p A261 MAR 11 2008
A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with cle novo native coronary artery lesions. Ruygrok Peter(Reprint). Auckland City Hosp, Auckland, New Zealand Journal: Journal of the American College of Cardiology 49 ( 9, Suppl. B ): p 28B-29B MAR 6 2007 2007 i2 Summit 2007 on Innovation in Intervention New Orleans, LA, USA March 24 -27, 2007; 20070324 ISSN: 0735-1097
Serruys, P. SPIRIT II Study: A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions. European Society of Cardiology - ESC Congress 2006
Claessen, BE. et. al. Two Year Clinical, Angiographic and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With de novo Native Coronary Artery Lesions: The SPIRIT II Trial. Circ Cardiovasc Interventions. 2009. 339-347.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):